American College of Neuropsychopharmacology Inc. Neuropsychopharmacology
subscribe to npp
SEARCH
Advanced search
My Account E-alerts Subscribe Register Help
Journal home
Current Issue
Advance Online Publication
Archive
Online sample issue FREE!
Author index
Keyword index
For authors
Editorial Board
Instructions for authors
Aims and scope
Indexed in
Author queries
Online Submission
Customer Services
Subscription information
Journal prices
Order sample issue
Purchase articles,
reprints & permissions
Advertising
Contact NPG
nature.com
Neuropsychopharmacology (1996) 15 541-554.

Temporal Lobe Metabolic Differences in Medication-Free Outpatients with Schizophrenia via the PET-600

Thomas E Nordahl MD, Ph.D1,2, Natalia Kusubov MT(ASCP)1, Cameron Carter MBBS2, Shahriar Salamat MD, Ph.D5, Anne M Cummings MD2, Linda O'Shora-Celaya RNC2, Jamie Eberling Ph.D1, Lynn Robertson Ph.D3,4, Ronald H Huesman Ph.D1, William Jagust MD3 and Thomas F Budinger MD, Ph.D1
1From the Center for Functional Imaging, Lawrence Berkeley National Laboratory, University of California, Berkeley
2Department of Psychiatry, University of California, Davis
3Department of Neurology, University of California, Davis
4Center for Neuroscience, University of California, Davis
5Department of Pathology, University of California, Davis

Correspondence: Thomas E Nordahl, Center for Functional Imaging, 55-121, Lawrence Berkeley National Laboratory, 1 Cyclotron Road, Berkeley, CA 94720

Presented in part at the 1992 and 1993 American College of Neuropsychopharmacology and at the 1993 meeting of the American Psychiatry Association. This study was funded in large part by NIMH grant MH-46990.

SS is now in the Department of Surgical Pathology, Clinical Science Center, University of Wisconsin, Madison WI. CC is now with the Department of Psychiatry, University Pittsburgh Medical Center, Western Psychiatric Inst. and Clinic, Pittsburgh, PA.
ABSTRACT

Regional cerebral glucose metabolic rates (rCMRglc) were compared in 18 unmedicated outpatients with schizophrenia and 11 normal controls using high resolution positron emission tomography (PET) and the tracer [F-18]-2-fluoro-2D-deoxyglucose (FDG). From previous work we expected to see abnormal hippocampal rCMRglc in the patients, but no striatal abnormalities. Trial-by-trial Stroop cognitive task, which has been shown to activate the anterior cingulate, was performed within a day of the PET study. As our patients performed abnormally on the Stroop we tested for a correlation between the anterior cingulate rCMRglc and Stroop performance. We found no whole slice cortical average glucose metabolic abnormalities. As predicted we found abnormally decreased left hippocampal rCMRglc in the patients. No striatal or cingulate rCMRglc abnormalities were noted in patients, but they demonstrated a highly positive correlation between anterior and cingulate rCMRglc and Stroop facilitation. Patients with higher Stroop interference had more prominent hippocampal metabolic decreases. These localized temporal lobe abnormalities could account for some of the patient's positive symptoms and are consistent with recent findings in the literature. Ó American College of Neuropsychopharmacology

Keywords: Schizophrenia; Positron emission tomography (PET); [F-18]-2-D-deoxyglucose (FDG); Temporal lobe; Repeated measures ANOVA
  top go to top
Article Links
Send to a friend Send to a friend
Download PDF Download PDF
 Next Article Next Article
 Previous Article Previous Article
 Table of Contents Table of Contents
Privacy Policy Copyright © 1996 by the American College of Neuropsychopharmacology